Categories
Change Password!
Reset Password!
Metoclopramide seems to be
an effective for acute migraine
treatment with no serious adverse events.
No
difference between intravenous metoclopramide and placebo concerning the safety
and efficacy in acute migraine patients, observed as explained in a randomized,
placebo‐controlled study published in 'Acta Neurologica Scandinavica'.
This
study focused on examining the efficacy and safety of intravenous
metoclopramide for acute migraine treatment.
A
double‐blind, randomized, parallel‐group, placebo‐controlled trial was executed
in an academic emergency department. The patients were randomized into
intravenous metoclopramide 10 mg and normal saline groups after being evaluated
for eligibility via the International Headache Society criteria for migraines.
An 11‐point numeric rating scale (NRS) score was used to assess the headache
intensity. The median between‐group change in the score at the 30th minute
helped determine the primary outcome measure. Adverse events, rescue medication
needs and emergency department (ED) revisits after the discharge comprised of
secondary outcome measures.
Total of
148 patients was randomized into two equal groups with similar baseline
characteristics, comprising the baseline NRS scores (8 points). The median
reduction in the NRS scores at the 30th minute was 4 [interquartile range
(IQR): 2‐6)] in the metoclopramide group and 3 (IQR: 1‐4) as observed in the
usual saline group. There were no serious adverse events and rescue medication
needs were similar in both groups.
Acta Neurologica Scandinavica
Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo‐controlled trial
Nurettin Özgür Doğan et al.
Comments (0)